NCT00673062已完成2 期
Study of the Decongestant Effect of SCH 900538 Compared With Placebo and Pseudoephedrine as Active Control in Subjects With Seasonal Allergic Rhinitis (SAR) Exposed to Pollen in an Environmental Exposure Unit
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 265
- 主要终点
- Average change from baseline in nasal congestion scores over the first 4-hour observation period.
研究概览
简要总结
This study is to evaluate the effectiveness of a new drug on congestion in subjects with seasonal allergic rhinitis. This effect will be compared to placebo and to the decongestant, pseudoephedrine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be 18 to 65 years of age, of either sex, and of any race.
- •Subjects must have a history of SAR due to ragweed for the last two consecutive ragweed seasons.
- •Subjects must be skin-test positive for the ragweed pollen allergen used in the Environmental Exposure Unit (pollen chamber at the Screening Visit or within 12 months prior to the Screening Visit.
- •Subjects must develop a pre-defined severity of allergy symptoms within 90-minute after entering the pollen chamber during the pollen challenge at the Priming visit (Visit 2), and prior to dosing (Visit 3), in order to qualify for the study.
- •Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test prior to randomization at the Treatment Visit. Female subjects and female partners of male subjects must be using an acceptable form of birth control during the study.
- •Blood pressure and pulse rate must be within normal ranges.
排除标准
- •Subjects who have had an upper or lower respiratory tract infection within approximately 28 days (4 weeks) before Priming (Visit 2) and thereafter.
- •Subjects who have a dependence upon nasal, oral, or ocular decongestants, nasal topical antihistamines, or nasal steroids, in the opinion of the investigator.
- •Subjects with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
- •Subjects who have used any investigational drugs, including placebo, within 30 days of Screening or for the duration of this stud, or who are participating in any other clinical study.
- •Subjects with a history of rhinitis medicamentosa.
- •Subjects with a history of anaphylaxis or severe or serious reaction to skin testing.
- •Subjects who are being medically treated for any of the following conditions: narrow-angle glaucoma, increased intraocular pressure, urinary retention, hypertension, severe coronary artery disease, ischemic heart disease, diabetes mellitus, hyperthyroidism, renal impairment, or prostatic hypertrophy; current treatment with monoamine oxidase (MAO) inhibitors.
- •Subjects with a history of a positive test, or are symptomatic, for HIV, TB (not due to vaccination), and hepatitis B (not due to vaccination) or hepatitis C.
- •Subjects with asthma that requires medication other than occasional (<=3 uses per week) use of an inhaled short-acting b-2 agonist.
研究组 & 干预措施
Placebo Capsules
Placebo Comparator
干预措施: Placebo Capsules (Drug)
SCH 900538
Experimental
干预措施: SCH 900538 (Drug)
Encapsulated pseudoephedrine
Active Comparator
Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
干预措施: Pseudoephedrine (Drug)
结局指标
主要结局
Average change from baseline in nasal congestion scores over the first 4-hour observation period.
时间窗: Over the first 4-hour observation period.
次要结局
- Average change from baseline in total symptoms, total symptoms minus congestion, total nasal symptoms, total nasal symptoms minus congestion, total non-nasal symptoms, and individual symptoms scores.(Over the first 4 hour and 12-hour study periods.)
- Average change from baseline in nasal congestion at each evaluation time point.(Over 12 hours.)
- Onset of action: defined as the first time point at which a sustained, statistically significant (P<=0.05) reduction relative to placebo in an efficacy variable (eg, nasal congestion) up to a pre-specified time point.(Over the first 4-hours and 12-hour study periods.)
- Average change from baseline in PNIF over the first 4-hour and 12-hour study periods and at each time point.(Over the first 4-hour and 12-hour study periods.)
研究者
相似试验
已完成
4 期
To Determine if Diphenhydramine Works for Nasal Congestion at Two Different DosesNasal CongestionNCT00648973Johnson & Johnson Consumer and Personal Products Worldwide1,021
尚未招募
不适用
Development of a Clinical Screening, Diagnostic and Evaluation Tool for Patients With Lower Limb Lymphedema: Aim 4Lower Limb LymphedemaNCT06038864KU Leuven120
已完成
不适用
asal decongestant study: a prospective double-blind randomised comparative study of nasal decongestant and vasoconstrictive efficacy of two commonly used preparations, namely cocaine and adrenaline, with normal saline and adrenaline with normal salineSurgery: NoseSurgeryNoseISRCTN24006995Record Provided by the NHSTCT Register - 2007 Update - Department of Health
Unknown
不适用
Effects of Complex Decongestive Therapy Applied on Patients With Lower Extremity LymphedemaLymphedemaNCT05239273Ankara Yildirim Beyazıt University40
已完成
3 期
Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer "DELTA STUDY"LymphedemaBreast CancerNCT00201890Ontario Clinical Oncology Group (OCOG)103